Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Endometrial Neoplasms 7 Ovarian Neoplasms 6 Neoplasms 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 3 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Lung Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Neuroendocrine 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Turcot syndrome 1 Small Cell Lung Carcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1 Recurrence 1 Penile Neoplasms 1 Pathologic Complete Response 1 Neoplasms, Second Primary 1 Mesothelioma, Malignant 1 Mesothelioma 1 Melanoma 1 MMRd/MSI-H Stage II-III Endometrial Cancer 1

Interventions

Nivolumab 5 pembrolizumab 3 avelumab 3 Neoadjuvant Therapy 3 toripalimab 2 durvalumab 2 atezolizumab 2 Celecoxib 2 spartalizumab 1 relatlimab 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 danvatirsen 1 XELOX 1 Surgical Procedures, Operative 1 Oxaliplatin 1 Leucovorin 1 Ipilimumab 1 Induction Chemotherapy 1 Immunotherapy 1 Immunoglobulin G 1 Immune Checkpoint Inhibitors 1 IMM-101 1 Fluorouracil 1 Docetaxel 1 Disulfides 1 DEAE-Dextran 1 Cyclophosphamide 1 Chemotherapy, Adjuvant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Turcot syndrome × dostarlimab × Clear all

NCT06278857 2024-12-03

SATELLITE

Queensland Centre for Gynaecological Cancer

Phase 2 Recruiting

Turcot syndrome, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡